Objective: Raynaud's phenomenon (RP) is an important clinical feature of systemic sclerosis (SSc) for which consistently effective therapies are lacking. The study was designed to assess the safety, tolerability, and efficacy of tadalafil, a selective, long acting type V cyclic GMP phosphodiesterase (PDE-5) inhibitor, in this clinical syndrome.
Methods: We performed a prospective, randomized, double-blind, placebo-controlled, crossover study comparing oral tadalafil at a fixed dose of 20 mg daily for a period of 4 weeks versus placebo in women with RP secondary to SSc.
Results: Thirty-nine subjects completed the study and were evaluable. There were no statistically significant differences in Raynaud Condition Score (RCS), frequency of RP episodes, or duration of RP episodes between treatment groups. Placebo response was a confounding factor. Tadalafil was well tolerated.
Conclusion: Tadalafil appears to be safe and well tolerated but lacks efficacy in comparison to placebo as a treatment for RP secondary to SSc.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.090270 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of metformin on postprandial blood pressure, heart rate, gastric emptying, GLP-1 and the prevalence of postprandial hypotension in type 2 diabetes - a double-blind, placebo-controlled crossover study.
Diabetes
January 2025
Adelaide Medical School and Centre of Research Excellence (CRE) in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia.
Individuals with type 2 diabetes are at high risk of postprandial falls in blood pressure (BP) (i.e., a reduction in systolic BP of ≥20mmHg, termed postprandial hypotension (PPH)), which increases the risk of falls and mortality.
View Article and Find Full Text PDFAn Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.
JAMA Neurol
January 2025
Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.
Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.
Design, Setting, And Participants: This phase 2 randomized double-blind placebo-controlled crossover clinical trial was conducted from October 21, 2020, to February 27, 2023, at 19 sites in the US.
Visual function and vehicle driving performance under the effects of cannabidiol: A randomized cross-over experiment.
Addiction
January 2025
Department of Optics, Laboratory of Vision Sciences and Applications, University of Granada, Granada, Spain.
Aims: This study aimed to determine the effect of vaporized cannabidiol (CBD) on visual function and vehicle driving performance, given the growing popularity of CBD use worldwide.
Design: Randomized, double-blind, placebo-controlled cross-over experimental study.
Setting: Laboratory of Vision Sciences and Applications, University of Granada, Spain.
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial.
Nat Med
January 2025
Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Article Synopsis
- A study investigated the effectiveness of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, in preventing kidney stones in nondiabetic adults with a history of calcium or uric acid stones.
- The trial involved 53 participants who were given either empagliflozin or a placebo in a crossover design, focusing on changes in urine supersaturation ratios relevant to stone recurrence.
- Results showed significant reductions in urine supersaturation ratios for calcium phosphate in calcium stone formers and uric acid in uric acid stone formers, indicating that empagliflozin may help prevent certain types of kidney stones without serious side effects.
Effects of New Zealand Black Currant Extract on Exercising Substrate Utilization and Postexercise Blood Pressure in Men and Women.
Int J Sport Nutr Exerc Metab
January 2025
Institute of Applied Sciences, University of Chichester, Chichester, United Kingdom.
New Zealand black currant extract (NZBC) has been shown to increase fat oxidation during exercise and decrease the postexercise blood pressure in men and women. The change in fat oxidation by NZBC has also been shown to be correlated to body composition in men and women. There has never been a comparison of sex responses within the same study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!